

**Mo-99 2016 TOPICAL MEETING ON
MOLYBDENUM-99 TECHNOLOGICAL DEVELOPMENT**

**SEPTEMBER 11-14, 2016
THE RITZ-CARLTON
ST. LOUIS, MISSOURI**

Progress on LEU TechneLite® Generators

Ira N. Goldman¹, Kathleen Mcfadden²

¹Manufacturing and Operations

²Sales and Marketing Lantheus Medical Imaging
331 Treble Cove Road, N. Billerica, MA 01862 – USA

ABSTRACT

In January 2013 Lantheus Medical Imaging, Inc. began manufacturing the TechneLite® (Technetium TC^{99m}) generator using Molybdenum-99 (Mo⁹⁹) produced from low-enriched uranium (LEU). For the past three and a half years the LEU TechneLite® generator has been manufactured in a weekly, dedicated manufacturing run. Over this period both the Mo⁹⁹ supply chain has become more secure and reliable and there has been marked increase in customer demand. The centers for Medicare and Medicaid services (CMS) recently proposed to continue in 2017 the \$10 add-on payment for non-HEU derived doses that was initiated as a part of the hospital outpatient prospective payment system (HOPPS) in 2013.

This paper will describe supply chain and commercial progress regarding LEU TechneLite® since the 2015 DOE Topical Meeting in Boston, including Lantheus's continuing transition toward an all-LEU Mo⁹⁹ Supply Chain.